Journal Watch · Diabetes Care · 2026

Longitudinal Analysis of Liver Chemistry Trajectories and Risk of Type 2 Diabetes in Children With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Cohort Study.

Further validation in independent cohorts is needed to confirm these findings and inform clinical application.

Thai NQN, Chun LF, Newton KP et al.Diabetes Care3 min readPharma relevance 40/100

DOI: 10.2337/dc25-1532PMID: 41364086Study type: cohort / observational clinical study

TL;DR

Further validation in independent cohorts is needed to confirm these findings and inform clinical application.

Key findings

  • Together with AST, GGT may provide clinicians with concrete, routinely available parameters to monitor for early risk stratification.
  • Further validation in independent cohorts is needed to confirm these findings and inform clinical application.

Numbers at a glance (from the abstract)

12.3%95%HR 1.31HR 1.13

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Extended Cox models with inverse probability weighting were used to evaluate associations between liver enzyme trajectories and type 2 diabetes risk.<h4>Results</h4>The cumulative incidence of type 2 diabetes was 12.3%. Increases in GGT (hazard ratio [HR] 1.55; 95% CI 1.34-1.80), AST (HR 1.31; 95% CI 1.20-1.43), and ALT (HR 1.13; 95% CI 1.07-1.20) were associated with a higher risk of developing type 2 diabetes in the independent models. In the mutual model with all three liver chemistries, only GGT and AST remained significant.<h4>Conclusions</h4>A 30-unit increase in GGT over time was associated with a substantially higher risk of developing type 2 diabetes in children with MASLD.

Full abstract (original)

Background: <h4>Objective</h4>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children and is linked to type 2 diabetes. This study evaluates whether longitudinal changes in liver chemistries-γ-glutamyl transferase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT)-can serve as biomarkers of increased type 2 diabetes risk in children with MASLD.<h4>Research design and methods</h4>This multicenter longitudinal cohort study followed 1,035 children with biopsy-confirmed MASLD, without type 2 diabetes at baseline, for a mean of 3.9 years. Liver chemistries were measured annually, and type 2 diabetes was diagnosed based on fasting glucose, HbA1c, and clinical diagnosis.

What they did: Extended Cox models with inverse probability weighting were used to evaluate associations between liver enzyme trajectories and type 2 diabetes risk.<h4>Results</h4>The cumulative incidence of type 2 diabetes was 12.3%. Increases in GGT (hazard ratio [HR] 1.55; 95% CI 1.34-1.80), AST (HR 1.31; 95% CI 1.20-1.43), and ALT (HR 1.13; 95% CI 1.07-1.20) were associated with a higher risk of developing type 2 diabetes in the independent models. In the mutual model with all three liver chemistries, only GGT and AST remained significant.<h4>Conclusions</h4>A 30-unit increase in GGT over time was associated with a substantially higher risk of developing type 2 diabetes in children with MASLD.

Results & conclusions: Together with AST, GGT may provide clinicians with concrete, routinely available parameters to monitor for early risk stratification. Further validation in independent cohorts is needed to confirm these findings and inform clinical application.

Abstract © the authors / Diabetes Care (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.2337/dc25-1532 · PubMed 41364086.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Diabetes Care for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Diabetes Care study find?

Further validation in independent cohorts is needed to confirm these findings and inform clinical application.

What type of study is this?

It is a cohort / observational clinical study, published in Diabetes Care in 2026. Extended Cox models with inverse probability weighting were used to evaluate associations between liver enzyme trajectories and type 2 diabetes risk.<h4>Results</h4>The cumulative incidence of type 2 diabetes was 12.3%.

Where can I read the original paper?

The original is at the publisher via DOI 10.2337/dc25-1532. PubMed ID: 41364086. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Thai NQN, Chun LF, Newton KP et al.. Longitudinal Analysis of Liver Chemistry Trajectories and Risk of Type 2 Diabetes in Children With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Cohort Study.. Diabetes Care (2026). DOI: 10.2337/dc25-1532.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/longitudinal-analysis-of-liver-chemistry-trajectories-and-risk-of-type-2-251532/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides